Fluidigm to Present at Upcoming Health Care Investor Conferences
Fluidigm Corporation (Nasdaq: FLDM) announced key presentations by CEO Chris Linthwaite and CFO Vikram Jog at upcoming investor conferences. They will provide updates on the company’s business strategy and financial performance.
The presentations are scheduled for the UBS Virtual Global Healthcare Conference on May 19, 2020, at 4:40 PM ET, and the Jefferies Virtual Healthcare Conference on June 3, 2020, at 3:00 PM ET. Live webcasts will be available on the company’s investor website and archived for 30 days post-event.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that Chris Linthwaite, President and Chief Executive Officer, and Vikram Jog, Chief Financial Officer, will present updates regarding Fluidigm’s business strategy and financial performance at the following upcoming investor conferences:
- UBS Virtual Global Healthcare Conference, on Tuesday, May 19, 2020, at 4:40 p.m. ET.
- Jefferies Virtual Healthcare Conference, on Wednesday, June 3, 2020, at 3:00 p.m. ET.
A live webcast of each presentation and subsequent replay will be available in the Events & Presentations section of the Company’s investor website. Each webcast will be archived for 30 days following the live presentation.
About Fluidigm
Fluidigm (Nasdaq:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
Available Information
We use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Contact:
Fluidigm Corporation
Agnes Lee
Vice President, Investor Relations
650 416 7423
agnes.lee@fluidigm.com
FAQ
What is Fluidigm's upcoming conference schedule for May and June 2020?
Who will represent Fluidigm at the investor conferences in May and June 2020?
Where can I watch the Fluidigm presentations from the investor conferences?
What is the focus of Fluidigm's business strategy presentation?
What technologies does Fluidigm focus on in its research?
